PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
-0.08%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$2.82B
AUM Growth
+$2.82B
(-21%)
Cap. Flow
-$412M
Cap. Flow
% of AUM
-14.61%
Top 10 Holdings %
Top 10 Hldgs %
54.76%
Holding
113
New
15
Increased
15
Reduced
28
Closed
26
Top Buys
| 1 |
Edgewise Therapeutics
EWTX
|
$85M |
| 2 |
Insmed
INSM
|
$27.9M |
| 3 |
BBNX
Beta Bionics, Inc. Common Stock
BBNX
|
$19.5M |
| 4 |
Dyne Therapeutics
DYN
|
$18.5M |
| 5 |
Solid Biosciences
SLDB
|
$18.5M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$69.9M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$66.2M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$60M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$47.6M |
| 5 |
Insulet
PODD
|
$42.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Akero Therapeutics
AKRO
$3.65B
| $32.1M | 1.13% |
792,960
-392,632
| -33% | -$15.9M |
|
27
Merus
MRUS
$5.04B
| $29.1M | 1.03% |
690,485
+390,485
| +130% | +$16.4M |
|
28
Amylyx Pharmaceuticals
AMLX
$877M
| $27.9M | 0.98% |
7,874,348
+1,100,000
| +16% | +$3.89M |
|
29
ADMA Biologics
ADMA
$4.03B
| $27.2M | 0.96% |
1,373,233
+482,953
| +54% | +$9.58M |
|
30
Vaxcyte
PCVX
$4.17B
| $26.7M | 0.94% |
706,567
-1,011,850
| -59% | -$38.2M |
|
31
Janux Therapeutics
JANX
$1.38B
| $26.2M | 0.93% |
970,412
+152,517
| +19% | +$4.12M |
|
|
32
Dyne Therapeutics
DYN
$1.92B
| $24.2M | 0.85% |
2,313,403
+1,770,126
| +326% | +$18.5M |
|
33
Celcuity
CELC
$2.3B
| $23.9M | 0.84% |
2,362,279
| – | – |
|
34
Zymeworks
ZYME
$1.07B
| $22.2M | 0.78% |
1,864,672
-265,348
| -12% | -$3.16M |
|
35
Intuitive Surgical
ISRG
$158B
| $20.1M | 0.71% |
40,619
-22,500
| -36% | -$11.1M |
|
36
Orchestra BioMed
OBIO
$147M
| $19.7M | 0.69% |
4,592,556
| – | – |
|
|
BBNX
37
Beta Bionics, Inc. Common Stock
BBNX
$855M
| $19.5M | 0.69% |
+1,593,608
| New | +$19.5M |
|
|
38
Insulet
PODD
$24.2B
| $18.8M | 0.66% |
71,597
-160,672
| -69% | -$42.2M |
|
39
Repligen
RGEN
$6.54B
| $16.5M | 0.58% |
+129,801
| New | +$16.5M |
|
|
DRUG
40
Bright Minds Biosciences
DRUG
$307M
| $16M | 0.57% |
444,649
+41,000
| +10% | +$1.48M |
|
41
Madrigal Pharmaceuticals
MDGL
$9.7B
| $15.4M | 0.54% |
+46,500
| New | +$15.4M |
|
42
Inhibrx
INBX
$403M
| $14.9M | 0.53% |
1,064,026
| – | – |
|
43
Boston Scientific
BSX
$159B
| $13.1M | 0.46% |
+130,000
| New | +$13.1M |
|
|
SION
44
Sionna Therapeutics, Inc. Common Stock
SION
$1.08B
| $13.1M | 0.46% |
+1,251,101
| New | +$13.1M |
|
45
Inhibikase Therapeutics
IKT
$129M
| $13M | 0.46% |
5,925,000
| – | – |
|
46
Viking Therapeutics
VKTX
$3.02B
| $12.3M | 0.43% |
509,005
-486,889
| -49% | -$11.8M |
|
47
DexCom
DXCM
$30.9B
| $12.2M | 0.43% |
+178,000
| New | +$12.2M |
|
48
Neurocrine Biosciences
NBIX
$13.5B
| $11.1M | 0.39% |
100,050
| – | – |
|
49
Xenon Pharmaceuticals
XENE
$2.99B
| $10.9M | 0.39% |
325,324
| – | – |
|
50
Acrivon Therapeutics
ACRV
$42.2M
| $10.9M | 0.38% |
5,360,858
| – | – |
|